Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.

Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht AA, Bowen D, de Witte T, Garcia-Manero G, Hellström-Lindberg E, Germing U, Stauder R, Malcovati L, Sekeres M, Steensma DP, Gloaguen S.

Blood. 2018 Nov 7. pii: blood-2018-06-857102. doi: 10.1182/blood-2018-06-857102. [Epub ahead of print]

PMID:
30404811
2.

Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes.

Rydén J, Edgren G, Karimi M, Walldin G, Tobiasson M, Wikman A, Hellström-Lindberg E, Höglund P.

Leukemia. 2018 Sep 28. doi: 10.1038/s41375-018-0256-0. [Epub ahead of print] No abstract available.

PMID:
30267009
3.

Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia.

Shiozawa Y, Malcovati L, Gallì A, Sato-Otsubo A, Kataoka K, Sato Y, Watatani Y, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Makishima H, Shiraishi Y, Chiba K, Hellström-Lindberg E, Miyano S, Ogawa S, Cazzola M.

Nat Commun. 2018 Sep 7;9(1):3649. doi: 10.1038/s41467-018-06063-x.

4.

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes.

Itzykson R, Crouch S, Travaglino E, Smith A, Symeonidis A, Hellström-Lindberg E, Sanz G, Čermák J, Stauder R, Elena C, Germing U, Mittelman M, Langemeijer S, Mądry K, Tatic A, Holm MS, Almeida AM, Savic A, Šimec NG, Luño E, Culligan D, Guerci-Bresler A, Malcovati L, van Marrewijk C, Bowen D, de Witte T, Fenaux P; European MDS Registry members.

Blood Adv. 2018 Aug 28;2(16):2079-2089. doi: 10.1182/bloodadvances.2018020495.

5.

appreci8: A Pipeline for Precise Variant Calling Integrating 8 Tools.

Sandmann S, Karimi M, de Graaf AO, Rohde C, Göllner S, Varghese J, Ernsting J, Walldin G, van der Reijden BA, Müller-Tidow C, Malcovati L, Hellström-Lindberg E, Jansen JH, Dugas M.

Bioinformatics. 2018 Jun 26. doi: 10.1093/bioinformatics/bty518. [Epub ahead of print]

PMID:
29945233
6.

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.

Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, Sanchi A, Radujkovic A, Horn P, Dolatshad H, Roy S, Broxholme J, Lockstone H, Taylor S, Giagounidis A, Vyas P, Schuh A, Hamblin A, Papaemmanuil E, Killick S, Malcovati L, Hennrich ML, Gavin AC, Ho AD, Luft T, Hellström-Lindberg E, Cazzola M, Smith CWJ, Smith S, Boultwood J.

Blood. 2018 Sep 20;132(12):1225-1240. doi: 10.1182/blood-2018-04-843771. Epub 2018 Jun 21.

PMID:
29930011
7.

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.

Moreno Berggren D, Folkvaljon Y, Engvall M, Sundberg J, Lambe M, Antunovic P, Garelius H, Lorenz F, Nilsson L, Rasmussen B, Lehmann S, Hellström-Lindberg E, Jädersten M, Ejerblad E.

Br J Haematol. 2018 Jun;181(5):614-627. doi: 10.1111/bjh.15243. Epub 2018 Apr 29.

PMID:
29707769
8.

Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells.

Guzzi N, Cieśla M, Ngoc PCT, Lang S, Arora S, Dimitriou M, Pimková K, Sommarin MNE, Munita R, Lubas M, Lim Y, Okuyama K, Soneji S, Karlsson G, Hansson J, Jönsson G, Lund AH, Sigvardsson M, Hellström-Lindberg E, Hsieh AC, Bellodi C.

Cell. 2018 May 17;173(5):1204-1216.e26. doi: 10.1016/j.cell.2018.03.008. Epub 2018 Apr 5.

PMID:
29628141
9.

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.

Stauder R, Yu G, Koinig KA, Bagguley T, Fenaux P, Symeonidis A, Sanz G, Cermak J, Mittelman M, Hellström-Lindberg E, Langemeijer S, Holm MS, Mądry K, Malcovati L, Tatic A, Germing U, Savic A, van Marrewijk C, Guerci-Bresler A, Luño E, Droste J, Efficace F, Smith A, Bowen D, de Witte T.

Leukemia. 2018 Jun;32(6):1380-1392. doi: 10.1038/s41375-018-0089-x. Epub 2018 Mar 6.

10.

Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm.

Xiao P, Dolinska M, Sandhow L, Kondo M, Johansson AS, Bouderlique T, Zhao Y, Li X, Dimitriou M, Rassidakis GZ, Hellström-Lindberg E, Minato N, Walfridsson J, Scadden DT, Sigvardsson M, Qian H.

Blood Adv. 2018 Mar 13;2(5):534-548. doi: 10.1182/bloodadvances.2017013599.

11.

Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.

Björklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, Cooley S, Miller JS, Klimkowska M, Schaffer M, Watz E, Wikström K, Blomberg P, Wahlin BE, Palma M, Hansson L, Ljungman P, Hellström-Lindberg E, Ljunggren HG, Malmberg KJ.

Clin Cancer Res. 2018 Apr 15;24(8):1834-1844. doi: 10.1158/1078-0432.CCR-17-3196. Epub 2018 Feb 14.

PMID:
29444931
12.

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.

de Swart L, Smith A, Haase D, Fenaux P, Symeonidis A, Cermak J, Sanz G, Stauder R, Mittelman M, Hellström-Lindberg E, Malcovati L, Langemeijer S, Skov-Holm M, Mądry K, Germing U, Almeida AM, Tatic A, Savic A, Šimec NG, van Marrewijk C, Guerci-Bresler A, Sanhes L, Luño E, Culligan D, Beyne-Rauzy O, Burgstaller S, Blijlevens N, Bowen D, de Witte T.

Leuk Res. 2018 Apr;67:21-26. doi: 10.1016/j.leukres.2018.01.022. Epub 2018 Jan 31.

13.

Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment.

Scharenberg C, Jansson M, Saft L, Hellström-Lindberg E.

Br J Haematol. 2018 Feb;180(4):526-533. doi: 10.1111/bjh.15094. Epub 2018 Jan 29.

PMID:
29377069
14.

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.

de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, Tatic A, Symeonidis A, Huls G, Cermak J, van de Loosdrecht AA, Garelius H, Culligan D, Macheta M, Spanoudakis M, Panagiotidis P, Krejci M, Blijlevens N, Langemeijer S, Droste J, Swinkels DW, Smith A, de Witte T; EUMDS Steering Committee.

Haematologica. 2018 Jan;103(1):69-79. doi: 10.3324/haematol.2017.171884. Epub 2017 Nov 9.

15.

Gene expression and risk of leukemic transformation in myelodysplasia.

Shiozawa Y, Malcovati L, Gallì A, Pellagatti A, Karimi M, Sato-Otsubo A, Sato Y, Suzuki H, Yoshizato T, Yoshida K, Shiraishi Y, Chiba K, Makishima H, Boultwood J, Hellström-Lindberg E, Miyano S, Cazzola M, Ogawa S.

Blood. 2017 Dec 14;130(24):2642-2653. doi: 10.1182/blood-2017-05-783050. Epub 2017 Nov 2. Erratum in: Blood. 2018 Aug 23;132(8):869-875.

PMID:
29097382
16.

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Sep 1;127(9):3557. doi: 10.1172/JCI96202. Epub 2017 Sep 1. No abstract available.

17.

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.

Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, Woll PS, Richards LA, Knezevic K, Chandrakanthan V, Thoms JAI, Tursky ML, Huang Y, Ali Z, Olivier J, Galbraith S, Kulasekararaj AG, Tobiasson M, Karimi M, Pellagatti A, Wilson SR, Lindeman R, Young B, Ramakrishna R, Arthur C, Stark R, Crispin P, Curnow J, Warburton P, Roncolato F, Boultwood J, Lynch K, Jacobsen SEW, Mufti GJ, Hellstrom-Lindberg E, Wilkins MR, MacKenzie KL, Wong JWH, Campbell PJ, Pimanda JE.

Cell Rep. 2017 Jul 18;20(3):572-585. doi: 10.1016/j.celrep.2017.06.067.

18.

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF.

J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2.

19.

Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells.

Liu LL, Béziat V, Oei VYS, Pfefferle A, Schaffer M, Lehmann S, Hellström-Lindberg E, Söderhäll S, Heyman M, Grandér D, Malmberg KJ.

Cancer Immunol Res. 2017 Aug;5(8):654-665. doi: 10.1158/2326-6066.CIR-16-0296. Epub 2017 Jun 21.

20.

SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells.

Mortera-Blanco T, Dimitriou M, Woll PS, Karimi M, Elvarsdottir E, Conte S, Tobiasson M, Jansson M, Douagi I, Moarii M, Saft L, Papaemmanuil E, Jacobsen SEW, Hellström-Lindberg E.

Blood. 2017 Aug 17;130(7):881-890. doi: 10.1182/blood-2017-03-776070. Epub 2017 Jun 20.

21.

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance.

de Swart L, Smith A, MacKenzie M, Symeonidis A, Neukirchen J, Mikulenková D, Vallespí T, Zini G, Paszkowska-Kowalewska M, Kruger A, Saft L, Fenaux P, Bowen D, Hellström-Lindberg E, Čermák J, Stauder R, Tatic A, Holm MS, Malcovati L, Mądry K, Droste J, Blijlevens N, de Witte T, Germing U.

Ann Hematol. 2017 Jul;96(7):1105-1112. doi: 10.1007/s00277-017-3009-7. Epub 2017 May 20.

22.

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Jun 1;127(6):2206-2221. doi: 10.1172/JCI91363. Epub 2017 Apr 24. Erratum in: J Clin Invest. 2017 Sep 1;127(9):3557.

23.

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.

Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, De Paepe A, Karimi M, Krjutskov K, Einarsdottir E, Grövdal M, Jansson M, Ben Azenkoud A, Corddedu L, Lehmann S, Ekwall K, Kere J, Hellström-Lindberg E, Ungerstedt J.

Oncotarget. 2017 Apr 25;8(17):28812-28825. doi: 10.18632/oncotarget.15807.

24.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

25.

Evaluating Variant Calling Tools for Non-Matched Next-Generation Sequencing Data.

Sandmann S, de Graaf AO, Karimi M, van der Reijden BA, Hellström-Lindberg E, Jansen JH, Dugas M.

Sci Rep. 2017 Feb 24;7:43169. doi: 10.1038/srep43169.

26.

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

J Intern Med. 2017 Mar;281(3):284-299. doi: 10.1111/joim.12579. Epub 2016 Dec 7.

27.

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.

Scharenberg C, Giai V, Pellagatti A, Saft L, Dimitriou M, Jansson M, Jädersten M, Grandien A, Douagi I, Neuberg DS, LeBlanc K, Boultwood J, Karimi M, Jacobsen SE, Woll PS, Hellström-Lindberg E.

Haematologica. 2017 Mar;102(3):498-508. doi: 10.3324/haematol.2016.152025. Epub 2016 Nov 24.

28.

Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.

Dimitriou M, Woll PS, Mortera-Blanco T, Karimi M, Wedge DC, Doolittle H, Douagi I, Papaemmanuil E, Jacobsen SE, Hellström-Lindberg E.

Oncotarget. 2016 Nov 8;7(45):72685-72698. doi: 10.18632/oncotarget.12234.

29.

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.

Botezatu L, Michel LC, Makishima H, Schroeder T, Germing U, Haas R, van der Reijden B, Marneth AE, Bergevoet SM, Jansen JH, Przychodzen B, Wlodarski M, Niemeyer C, Platzbecker U, Ehninger G, Unnikrishnan A, Beck D, Pimanda J, Hellström-Lindberg E, Malcovati L, Boultwood J, Pellagatti A, Papaemmanuil E, Le Coutre P, Kaeda J, Opalka B, Möröy T, Dührsen U, Maciejewski J, Khandanpour C.

Exp Hematol. 2016 Jul;44(7):590-595.e1. doi: 10.1016/j.exphem.2016.04.001. Epub 2016 Apr 11.

30.

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.

Tobiasson M, McLornan DP, Karimi M, Dimitriou M, Jansson M, Ben Azenkoud A, Jädersten M, Lindberg G, Abdulkadir H, Kulasekararaj A, Ungerstedt J, Lennartsson A, Ekwall K, Mufti GJ, Hellström-Lindberg E.

Oncotarget. 2016 Apr 19;7(16):22103-15. doi: 10.18632/oncotarget.7899.

31.

Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.

Sohlberg E, Pfefferle A, Andersson S, Baumann BC, Hellström-Lindberg E, Malmberg KJ.

Oncotarget. 2015 Oct 27;6(33):34178-90. doi: 10.18632/oncotarget.6213.

32.

Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts.

Conte S, Katayama S, Vesterlund L, Karimi M, Dimitriou M, Jansson M, Mortera-Blanco T, Unneberg P, Papaemmanuil E, Sander B, Skoog T, Campbell P, Walfridsson J, Kere J, Hellström-Lindberg E.

Br J Haematol. 2015 Nov;171(4):478-90. doi: 10.1111/bjh.13610. Epub 2015 Aug 10.

33.

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.

Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, Elena C, Gallì A, Walldin G, Della Porta MG, Raaschou-Jensen K, Travaglino E, Kallenbach K, Pietra D, Ljungström V, Conte S, Boveri E, Invernizzi R, Rosenquist R, Campbell PJ, Cazzola M, Hellström Lindberg E.

Blood. 2015 Jul 9;126(2):233-41. doi: 10.1182/blood-2015-03-633537. Epub 2015 May 8.

34.

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.

de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, Symeonidis A, Sanz G, Hellström-Lindberg E, Cermák J, Germing U, Stauder R, Georgescu O, MacKenzie M, Malcovati L, Holm MS, Almeida AM, Mądry K, Slama B, Guerci-Bresler A, Sanhes L, Beyne-Rauzy O, Luño E, Bowen D, de Witte T.

Br J Haematol. 2015 Aug;170(3):372-83. doi: 10.1111/bjh.13450. Epub 2015 Apr 24.

PMID:
25907546
35.

High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia.

Karimi M, Nilsson C, Dimitriou M, Jansson M, Matsson H, Unneberg P, Lehmann S, Kere J, Hellström-Lindberg E.

Haematologica. 2015 Jun;100(6):e223-5. doi: 10.3324/haematol.2014.118034. Epub 2015 Mar 13. No abstract available.

36.

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.

Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J.

Nat Commun. 2015 Jan 9;6:5901. doi: 10.1038/ncomms6901.

37.

Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes.

Ryblom H, Hast R, Hellström-Lindberg E, Winterling J, Johansson E.

Eur J Oncol Nurs. 2015 Apr;19(2):99-106. doi: 10.1016/j.ejon.2014.10.011. Epub 2014 Nov 5.

PMID:
25488465
38.

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.

Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A, Aul C, Selleslag D, Ferrant A, Marie JP, Amadori S, Jehn U, Mandelli F, Hess U, Hellström-Lindberg E, Cakmak-Wollgast S, Vignetti M, Labar B, Willemze R, de Witte T.

Ann Hematol. 2015 Jan;94(1):23-34. doi: 10.1007/s00277-014-2177-y. Epub 2014 Aug 7.

PMID:
25096636
39.

A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome.

Ueda Y, Calado RT, Norberg A, Kajigaya S, Roos G, Hellstrom-Lindberg E, Young NS.

BMC Med Genet. 2014 Jun 19;15:68. doi: 10.1186/1471-2350-15-68.

40.

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Eur J Haematol. 2014 Nov;93(5):439-45. doi: 10.1111/ejh.12383. Epub 2014 Jun 14.

PMID:
24853277
41.

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P, Hokland P, Holm MS, Cazzola M, Malcovati L, Tauro S, Bowen D, Boultwood J, Pellagatti A, Pimanda JE, Unnikrishnan A, Vyas P, Göhring G, Schlegelberger B, Tobiasson M, Kvalheim G, Constantinescu SN, Nerlov C, Nilsson L, Campbell PJ, Sandberg R, Papaemmanuil E, Hellström-Lindberg E, Linnarsson S, Jacobsen SE.

Cancer Cell. 2014 Jun 16;25(6):794-808. doi: 10.1016/j.ccr.2014.03.036. Epub 2014 May 15. Erratum in: Cancer Cell. 2015 Apr 13;27(4):603-5. Cancer Cell. 2014 Jun 16;25(6):861.

42.

Lung transplantation in telomerase mutation carriers with pulmonary fibrosis.

Silhan LL, Shah PD, Chambers DC, Snyder LD, Riise GC, Wagner CL, Hellström-Lindberg E, Orens JB, Mewton JF, Danoff SK, Arcasoy MO, Armanios M.

Eur Respir J. 2014 Jul;44(1):178-87. doi: 10.1183/09031936.00060014. Epub 2014 May 15.

43.

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.

Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, Selleslag D, Beyne-Rauzy O, te Boekhorst P, del Cañizo C, Guerci-Bresler A, Nilsson L, Lübbert M, Quesnel B, Ganser A, Bowen D, Schlegelberger B, Göhring G, Fu T, Benettaib B, Hellström-Lindberg E, Fenaux P.

Eur J Haematol. 2014 Nov;93(5):429-38. doi: 10.1111/ejh.12380. Epub 2014 Jun 9.

44.

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, Göhring G, Giagounidis A, Selleslag D, Muus P, Sanz G, Mittelman M, Bowen D, Porwit A, Fu T, Backstrom J, Fenaux P, MacBeth KJ, Hellström-Lindberg E.

Haematologica. 2014 Jun;99(6):1041-9. doi: 10.3324/haematol.2013.098103. Epub 2014 Mar 28.

45.

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.

Tobiasson M, Dybedahl I, Holm MS, Karimi M, Brandefors L, Garelius H, Grövdal M, Högh-Dufva I, Grønbæk K, Jansson M, Marcher C, Nilsson L, Kittang AO, Porwit A, Saft L, Möllgård L, Hellström-Lindberg E.

Blood Cancer J. 2014 Mar 7;4:e189. doi: 10.1038/bcj.2014.8.

46.

Erythropoiesis stimulating agents and other growth factors in low-risk MDS.

Hellström-Lindberg E, van de Loosdrecht A.

Best Pract Res Clin Haematol. 2013 Dec;26(4):401-10. doi: 10.1016/j.beha.2013.09.007. Epub 2013 Oct 2. Review.

PMID:
24507816
47.

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.

Fenaux P, Seymour JF, Santini V, Silverman L, Gore S, List A, Sanz G, Mufti GJ, Estey E, Swern AS, Beach CL, Hellstrom-Lindberg E.

Leuk Res. 2014 Feb;38(2):258-62. doi: 10.1016/j.leukres.2013.10.014. Epub 2013 Oct 27.

48.

Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients.

Bowen DT, Hellström-Lindberg E, Steensma DP.

Br J Haematol. 2014 Feb;164(4):610-1. doi: 10.1111/bjh.12655. Epub 2013 Nov 15. No abstract available.

PMID:
24236802
49.

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mudie LJ, McLaren S, Hardy C, Latimer C, Della Porta MG, O'Meara S, Ambaglio I, Galli A, Butler AP, Walldin G, Teague JW, Quek L, Sternberg A, Gambacorti-Passerini C, Cross NC, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium.

Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886. Epub 2013 Sep 12.

50.

Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation.

Grövdal M, Karimi M, Tobiasson M, Reinius L, Jansson M, Ekwall K, Ungerstedt J, Kere J, Greco D, Hellström-Lindberg E.

Leukemia. 2014 Feb;28(2):411-3. doi: 10.1038/leu.2013.265. Epub 2013 Sep 12. No abstract available.

PMID:
24025691

Supplemental Content

Loading ...
Support Center